EconPapers    
Economics at your fingertips  
 

High Levels of Pro B-Type Natriuretic Peptides Are Associated with Adverse Outcomes in COVID-19 Disease: A Single Center Experience

Kashif Bin Naeem and Najiba Abdulrazzaq
Additional contact information
Kashif Bin Naeem: Al Kuwait Hospital, UAE
Najiba Abdulrazzaq: Al Kuwait Hospital, UAE

European Journal of Medical and Health Sciences, 2020, vol. 2, issue 5

Abstract: Coronavirus disease 2019 (COVID-19), caused by Severe Acute Respiratory Syndrome Coronavirus-2, has caused widespread morbidity and mortality worldwide. Cardiac injury is reported to be common in hospitalized patients. We evaluated whether Pro B-type Natriuretic Peptide (proBNP) levels measured on admission in COVID-19 patients were associated with worse outcomes. A retrospective analysis of laboratory-confirmed COVID-19 patients who were admitted between February 2020 and July 2020 to Al Kuwait Hospital, Dubai, UAE. Patients were divided into two groups: normal proBNP (≤125 ng/L) and high proBNP (>125 ng/L) upon admission. Clinical characteristics and outcomes were compared between the two groups. A total of 389 patients were studied. Overall, mean age was 50.2 years (range 16-94 years), 77.3% were males, 35.7% diabetics, 35.2% hypertensives and 5.6% had history of cardiovascular disease. Compared to the group with normal proBNP; patients with high proBNP on admission were: older, more diabetics and hypertensives, with more history of cardiovascular disease; they presented with abnormal chest radiograph; and had lower lymphocytes, higher neutrophils, lower eGFR, higher D-dimers, higher CRP and higher procalcitonin on admission laboratory tests. These patients had more risk of developing critical illness during the hospitalization, undergoing mechanical ventilation and risk of death. Elevated pro B-type natriuretic peptide levels on admission in COVID-19 patients may predict subsequent risk of developing critical illness, undergoing mechanical ventilation, and significant high risk of death.

Keywords: COVID-19; pro B-type natriuretic peptide; outcomes (search for similar items in EconPapers)
Date: 2020
References: Add references at CitEc
Citations:

Downloads: (external link)
https://eu-opensci.org/index.php/ejmed/article/view/40480 Abstract page (text/html)
https://eu-opensci.org/index.php/ejmed/article/download/40480/9038 Full text (application/pdf)

Related works:
This item may be available elsewhere in EconPapers: Search for items with the same title.

Export reference: BibTeX RIS (EndNote, ProCite, RefMan) HTML/Text

Persistent link: https://EconPapers.repec.org/RePEc:epw:ejmed0:v:2:y:2020:i:5:id:40480

DOI: 10.24018/ejmed.2020.2.5.480

Access Statistics for this article

More articles in European Journal of Medical and Health Sciences from European Open Science
Bibliographic data for series maintained by Support ().

 
Page updated 2026-06-22
Handle: RePEc:epw:ejmed0:v:2:y:2020:i:5:id:40480